Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Open Access Open Badges Pre-publication history

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Kim A Papp*, Darryl Toth and Les Rosoph

BMC Dermatology 2006, 6:9  doi:10.1186/1471-5945-6-9

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 11 May 2006
Reviewer's Report Dan Pearce 23 Jun 2006
Resubmission - Version 3 Manuscript Author's comment 25 Aug 2006
Reviewer's Report Jennifer Cather 13 Sep 2006
Reviewer's Report Dan Pearce 02 Oct 2006
Editorial acceptance 05 Oct 2006
Published 26 Oct 2006